Interferon beta in multiple sclerosis

Clinical Immunology and Immunopathology

Volumn 81, Issue 1, 1996, Pages 1-11

  Arnason, Barry G W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR;

HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0030271360     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0149     Document Type: Review

References (101)

1. 1. IFNB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655-661, 1993.
2. 2. Arnason, B. G. W., Interferon beta in multiple sclerosis. Neurology 43, 641-643, 1993.
3. 3. Paty, D. W., Li, D. K. B., and UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 662-669, 1993.
4. 4. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group, Interferon beta-1B in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45, 1277-1285, 1995.
5. 5. Jacobs, L., Cookfair, D., Rudick, R., Herndon, R., Richert, J., Salazar, A., Fischer, J., Granger, C., Simon, J., Goodkin, D., and MSCR Group, Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis [abstract]. Ann. Neurol. 36, 259, 1994.
6. 6. Arnason, B. G. W., and Reder, A. T., Interferons and multiple sclerosis. Clin. Neuropharmacol. 17, 495-547, 1994.
7. 7. Traugott, U., and Lebon, P., Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann. Neurol. 24, 243-251, 1988.
8. 8. Durelli, L., Bongioanni, M. R., Cavallo, R., Ferrero, B., Ferri, R., Ferrio, M. F., Bradac, G. B., Riva, A., Vai, S., Geuna, M., Bergamini, L., and Bergamasco, B., Chronic systemic high dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44, 406-413, 1994.
9. 9. Osborn, L., Kunkel, S., and Nabel, G. J., Tumor necrosis factor a and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor B. Proc. Natl. Acad. Sci. USA 86, 2336-2340, 1989.
10. 10. Traugott, U., and Lebon, P., Multiple sclerosis: Involvement of interferons in lesion pathogenesis. Ann. Neurol. 24, 243-251, 1988.
11. 11. Hofman, F. M., Hinton, D. R., Johnson, K., and Merrill, J. E., Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170, 607-612, 1989.
12. 12. Selmaj, K., Raine, C. S., Cannella, B., and Brosnan, C. F., Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87, 949-954, 1991.
13. 13. Stewart, II, W. E., Gosser, L. B., and Lockart Jr., R. Z., Priming: A nonantiviral function of interferon. J. Virol. 7, 792-801, 1971.
14. 14. Panitch, H. S., Hirsch, R. L., Haley, A. S., and Johnson, K. P., Exacerbations of multiple sclerosis with gamma interferon. Lancet 1, 893-895, 1987.
15. 15. Trotter, J. L., Collins, K. G., and van der Veen, R. C., Serum cytokine levels in chronic progressive multiple sclerosis: Interleukin-2 levels parallel tumor necrosis factor-α levels. J. Neuroimmunol. 33, 29-36, 1991.
16. 16. Beck, J., Rodot, P., Catinot, L., Falcoff, E., Kirchner, H., and Wietzerbin, J., Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 78, 318-323, 1988.
17. 17. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421, 1994.
18. 18. Hardy, K. J., and Sawado, T., Human γ interferon strongly upregulates its own gene expression in peripheral blood lymphocytes. J. Exp. Med. 170, 1021-1026, 1989.
19. 19. D'Cunha, J., Knight, Jr., E., Haas, A. L., Truitt, R. L., and Borden, E. C., Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl. Acad. Sci. USA 93, 211-215, 1996.
20. 20. Panitch, H. S., Bever, C. T., Katz, E., and Johnson, K. P., Upper respiratory tract infections trigger attacks of multiple sclerosis in patients treated with interferon-β [Abstract]. J. Neuroimmunol. 35(suppl 1), 125, 1991.
21. 21. DeSomer, P., Edy, V. G., and Billau, A., Interferon-induced skin reactivity in man. Lancet 2, 47-48, 1977.
22. 22. Spear, G. T., Paulnock, D. M., Jordan, R. L., Meltzer, D. M., Merritt, J. A., and Borden, E. C., Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo β-interferon. Clin. Exp. Immunol. 69, 107-115, 1987.
23. 23. Dayal, A., Jensen, M. A., Lledo, A., and Arnason, B. G. W., Interferon gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1B. Neurology 45, 2173-2177, 1995.
24. 24. Billiau, A., De Somer, P., Edy, V. G., De Clercq, E., and Heremans, H., Human fibroblast interferon for clinical trials: Pharmacokinetics and tolerability in experimental animals and humans. Antimicrob. Agents Chemother. 16, 56-63, 1979.
25. 25. Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., and Gutterman, J. U., Clinical toxicity of interferons in cancer patients: a review. J. Clin. Oncol. 4, 234-243, 1986.
26. 26. Sadovnik, A. D., Eisen, K., Ebers, G. C., and Paty, D. W., Cause of death in patients attending multiple sclerosis clinics. Neurology 41, 1192-1196, 1991.
27. 27. Levenson, J. L., and Fallon, H. J., Fluoxetine treatment of depression caused by interferon-α. Am. J. Gastroenterol. 88, 760-761, 1993.
28. 28. Pliskin, N. H., Towle, V. L., Hamer, D. P., Reder, A. T., Noronha, A., Pietre, S., and Arnason, B. G. W., The effects of interferon-beta on cognitive function in multiple sclerosis. Ann. Neurol. 36, 326, 1994. [Abstract]
29. 29. Smith, R. A., Norris, F., Palmer, D., Bernhardt, L., and Willis, R. J., Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin. Pharmacol. Ther. 37, 85-88, 1985.
30. 30. Hawkins, M. J., Krown, S. E., Borden, E. C., et al., American Cancer Society phase I trial of naturally produced β-interferon. Cancer Res. 44, 5934-5938, 1984.
31. 31. Lengyel, P., Biochemistry of interferons and their actions. Annu Rev. Biochem. 51, 251-282, 1982.
32. ser in healthy volunteers and its effect on serum neopterin. Pharmacol. Res. 10, 567-572, 1993.
33. 33. Burman, P., Tötterman, T. H., Öberg, K., and Karlsson, F. A., Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J. Clin. Endocrinol. Metab. 1086-1090, 1986.
34. 34. Mayet, W. J., Hess, G., Gerken, G., et al., Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10, 24-28, 1989.
35. 35. Ozawa, K., Suchanek, G., Breitschopf, H., Brück, W., Budka, H., Jellinger, K., and Lassmann, H., Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117, 1311-1322, 1994.
36. 36. Johnson, R. T., Griffin, D. E. Hirsch, R. L., et al., Measles encephalomyelitis: Clinical and immunologic studies. N. Engl. J. Med. 310, 137-141, 1984.
37. 37. Hemachudha, T., Griffin, D. E., Giffels, J. J., Johnson, R. T., Moser, A. B., and Phanuphak, P., Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. N. Engl. J. Med. 316, 369-374, 1987.
38. 38. Abreu, S. L., Interferon in experimental autoimmune encephalomyelitis (EAE): Effects of exogenous interferon on the antigen-enhanced adoptive transfer of EAE. Int. Arch. Allergy Appl. Immunol. 76, 302-307, 1985.
39. 39. Abreu, S. L., Tondreau, J., Levine, S., and Sowinski, R., Inhibition of passive localized experimental allergic encephalomyelitis by interferon. Int. Arch. Allergy Appl. Immunol. 72, 30-33, 1983.
40. 40. Panitch, H. S., and McFarlin, D. E., Experimental allergic encephalomyelitis: Enhancement of cell-mediated transfer by concanavalin A. J. Immunol. 119, 1134-1137, 1977.
41. 41. Willoughby, E. W., Grochowski, E., Li, D. K. B., Oger, J., Kastrakoff, L. F., and Paty, D. W., Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients. Ann. Neurol. 25, 43-49, 1989.
42. 42. Sibley, W. A., Bamford, C. R., and Clark, K., Clinical viral infections and multiple sclerosis. Lancet 1, 1313-1315, 1985.
43. 43. Andersen, O., Lygner, P-E., Bergström, T., Anderson, M., and Vahlne, A., Viral infections trigger multiple sclerosis relapses: a seroepidemiological study. J. Neurol. 240, 417, 1993.
44. 44. Basham, T. Y., and Merigan, T. C., Recombinant interferon-γ increases HLA-DR synthesis and expression. J. Immunol. 130, 1492-1494, 1983.
45. 45. Kelley, V. E., Fiers, W., and Strom, T. B., Cloned human interferon-γ, but not interferon -β or α, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J. Immunol. 132, 240-245, 1984.
46. 46. Armstrong, M. A., Crockard, A. D., Hawkins, S. A., and McNeill, T. A., Multiple sclerosis and gamma interferon. Lancet 1, 1369-1370, 1987.
47. 47. Ransohoff, R. M., Tuohy, V. K., Barna, B. P., and Rudick, R. A., Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vivo despite decreased HLA-DR density in vivo. J. Neuroimmunol. 37, 169-176, 1992.
48. 48. Ling, P. D., Warren, M. K., and Vogel, S. N., Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J. Immunol. 135, 1857-1863, 1985.
49. 49. Panitch, H. S., Folus, J. S., and Johnson, K. P., Beta interferon prevents HLA class II antigen induction by gamma interferon in MS. Neurology 39(suppl 1), 171, 1989.
50. 50. Sztein, M. B., Steeg, P. S., Johnson, H. M., and Oppenheim, J. R., Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons. J. Clin. Invest. 73, 556-565, 1984.
51. 51. Basham, T., Smith, W., Lanier, L., Morhenn, V., and Merigan, T., Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon. Hum. Immunol. 10, 83-93, 1984.
52. 52. Bluestone, J. A., New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2, 555-559, 1995.
53. 53. Gene, K., and Reder, A. T., IFN/β-1b reverses elevated lymphocyte B7-1 in MS. J. Neuroimmunol. 52(Suppl. 1), 20, 1995. [Abstract]
54. 54. Kuchroo, V. K., Das, M. P., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N., and Glimcher, L. H., B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 80, 707-718, 1995.
55. 55. Dayal, A., Qu, Z-X., Jensen, M., and Arnason, B. G. W., Transretinoic acid reverses induction of interferon γ-secreting cells by interferon β-1B. Neurology, in press.
56. 56. Ransohoff, R. M., and Estes, M. L., Astrocyte expression of major histocompatibility complex gene products in multiple sclerosis brain tissue obtained by stereotactic biopsy. Arch. Neurol. 48, 1244-1246, 1991.
57. 57. Traugott, U., and Lebon, P., Interferon-γ and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions. J. Neurol. Sci. 84, 257-264, 1988.
58. 58. Joseph, J., Knobler, R. L., D'Imperio, C., and Lublin, F. D., Down-regulation of interferon-γ-induced class II expression on human glioma cells by recombinant interferon-β: Effects of dosage treatment schedule. J. Neuroimmunol. 20, 39-44, 1988.
59. 59. Ransohoff, R. M., Devajyothi, C., Estes, M. L., Babcock, G., Rudick, R. A., Frohman, E. M, and Barna, B. P. Interferon-β specifically inhibits interferon-γ-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J. Neuroimmunol. 33, 103-112, 1991.
60. 60. Barna, B. P. Chou, S. M., Jacobs, B., Yen-Lieberman, B., and Ransohoff, R. M., Interferon-β impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J. Neuroimmunol. 23, 45-53, 1989.
61. 61. Korngold, R., Blank, K. J., and Murasko, D. M., Effect of interferon on thoracic duct lymphocyte output: induction with either poly 1: poly C or vaccinia virus. J. Immunol. 130, 2236-2240, 1983.
62. 62. Ishikawa, R., and Biron, C. A., IFN induction and associated changes in splenic leukocyte distribution. J. Immunol. 150, 3713-3727, 1993.
63. 63. Chin, Y. H., Cai, J-P., and Xu, X-M., Tissue-specific homing receptor mediates lymphocyte adhesion to cytokine-stimulated lymph node high endothelial venule cells. Immunology 74, 478-483, 1991.
64. 64. Rudick, R. A., Carpenter, C, S., Cookfair, D. L., Tuohy, V. K., and Ransohoff, R. M., In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 43, 2080-2087, 1993.
65. 65. Noronha, A., Toscas, A., and Jensen, M. A., Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J. Neuroimmunol. 46, 145-154, 1992.
66. 66. Kalaaji, A. N., Abernethy, N. J., McCullough, K., and Hay, J. B., Recombinant bovine interferon-α1 inhibits the migration of lymphocytes from lymph nodes but not into lymph nodes. Regional Immunol. 1, 56-61, 1988.
67. 67. Kimber, I., Sparshott, S. M., Bell, E. B., and Ford, W. L., The effects of interferon on the recirculation of lymphocytes in the rat. Immunology 60, 585-591, 1987.
68. 68. Pober, J. S., Gimbrone, M. A., Jr., Lapierre, L. A., et al., Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J. Immunol. 137, 1893-1896, 1986.
69. 69. May, M. J., and Ager, A., ICAM-1-independent lymphocyte transmigration across high endothelium: differential up-regulation by interferon γ, tumor necrosis factor-α and interleukin 1β. Eur. J. Immunol. 22, 219-226, 1992.
70. 70. Eguchi, K., Kawakami, A., Nakashima, M., Ida, H., Sakito, S., Matsuoka, N., Terada, K., Sakai, M., Kawabe, Y., Fukada, T., Ishimaru, T., Kurouji, K., Fujita, N., Aoyaji, T., Maeda, K., and Nagataki, S., Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells. Clin. Exp. Immunol. 88, 448-454, 1992.
71. 71. Noronha, A., Toscas, A., and Jensen, M. A., IFN-beta down-regulates IFN-gamma production by activated T cells in MS. Neurology 41, 219, 1991.
72. 72. Panitch, H. S., Folus, J. S., and Johnson, K. P., Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis. Ann. Neurol. 22, 139, 1987.
73. 73. Selmaj, K., Raine, C. S., Farooq, M., Norton, W. T., and Brosnan, C. F., Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J. Immunol. 147, 1522-1529, 1991.
74. 74. Selmaj K. W., and Raine, C. S., Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23, 339-346, 1988.
75. + current expression in cultured oligodendrocytes. J. Membr. Biol. 124, 127-137, 1991.
76. 76. Vartanian, T., Li, Y., Zhao, M. J., and Stefansson, K., Interferon-gamma-induced oligodendrocyte cell death: Implications for the pathogenesis of multiple sclerosis. Mol. Med. 1,7, 1995.
77. 77. Abu-khabar, K. S., Armstrong, J. A., and Ho, M., Type I interferons (IFN-A and -β) suppress cytotoxin (tumor necrosis factor-α and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J. Leukocyte Biol. 52, 162-172, 1992.
78. 78. Yoshida, R., Murray, H. W., and Nathan, C. F., Agonist and antagonist effects of interferon α and β on activation of human macrophages: two classes of interferon γ receptors and blockade of the high-affinity sites by interferon α or β. J. Exp. Med. 167, 1171-1185, 1988.
79. 1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA 88, 2918-2921, 1991.
80. 80. Boraschi, D. Ghezzi, P., Salmona, M., and Tagliabue, A., IFN-β-induced reduction of superoxide anion generation by macrophages. Immunology 45, 621-628, 1982.
81. 81. Nathan, C. F., Prendergast, T. J., Wiebe, M. E., et al., Activation of human macrophages: comparison of other cytokines with interferon-γ. J. Exp. Med. 160, 600-605, 1984.
82. 1. Neurology 41, 318, 1991.
83. 83. Racke, M. K., Dhib-Jalbut, S., Cannella, B., Albert, P. S., Raine, C. S., and McFarlin, D. E., Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J. Immunol. 146, 3012-3017, 1991.
84. 1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA 88, 2918-2921, 1991.
85. 85. Dore-Duffy, P., Perry, W., and Kuo, H-H., Interferon-mediated inhibition of prostaglandin synthesis in human mononuclear leukocytes. Cell Immunol. 79, 232-239, 1983.
86. 86. Noronha, A., Jensen, M., and Toscas, A., TGF-β activity in MS: Effect of IFN-β. Neurology 43(Suppl.), 355, 1993.
87. 87. Liu, Y., and Janeway, C. A., Jr., Interferon γ plays a critical role in induced cell death of effector T cells: a possible third mechanism of self-tolerance. J. Exp. Med. 172, 1735-1739, 1990.
88. 88. Ferber, I. A., Brocke, S., Taylor-Edwards, C., Ridgway, W., Dinisco, C., Steinman, L., Dalton, D., and Fathman, C. G., Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156, 5-7, 1996.
89. -/- mice. Science 256, 1210-1213, 1992.
90. 90. Arnason, B. G. W., and Antel, J. P., Suppressor cell function in multiple sclerosis. Ann. Immunol. (Paris) 129C, 159-170, 1987.
91. 91. Antel, J. P., Arnason, B. G. W., and Medof, M. E., Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann. Neurol. 5, 338-342, 1979.
92. 92. Antel, J. P., Bania, M. B., Reder, A., and Cashman, N., Activated suppressor cell dysfunction in progressive multiple sclerosis. J. Immunol. 137, 137-141, 1985.
93. 93. Noronha, A., Toscas, A., and Jensen, M. A., Interferon beta augments suppressor cell function in multiple sclerosis. Ann. Neurol. 27, 207-210, 1990.
94. 94. Noronha, A., Toscas, A., Arnason, B. G. W., and Jensen, M., IFN-beta augments in vivo suppressor function in MS [abstract]. Neurology 44(Suppl. 2), A212, 1994.
95. 95. Panitch, H. S., Folus, J. S., and Johnson, K. P., Activated suppressor cells inhibit synthesis of interferon γ in patients with multiple sclerosis and normal subjects. J. Neuroimmunol. 36, S186, 1991.[Abstract].
96. 96. Reder, A. T., IFNβ and IFNγ modify expression of monocyte surface proteins. J. Interferon Res. 11(Suppl. 1), 121, 1991.
97. 97. Barak, M., and Gruener, N., Neopterin augmentation of tumor necrosis factor production. Immunol. Lett. 30, 101-106, 1991.
98. 98. Moutabarrik, A., Takahara, S., Namiki, M., Kameoka, H., Seguchi, T., Yokokawa, K., Takano, Y., Sonada, T., Ishibashi, M., Zaid, D., et al., Contrasting effects of interferon-gamma and interleukin-4 on neopterin generation from human adhesion monocytes. Lymphokine Cytokine Res. 11, 327-330, 1992.
99. 99. Bell, G. M., and Imboden, J. B., CD2 and the regulation of T cell anergy. J. Immunol. 155, 2805-2807, 1995.
100. 100. Reder, A. T., Arnason, B. G. W., Maimone, D., Rohwer-Nutter, D., The function of the CD2 protein is abnormal in multiple sclerosis. J. Autoimmunity 4, 479-491, 1991.
101. 101. Qu, Z-W., Jensen, M. A., and Arnason, B. G. W., Retinoic acid potentiates the ability of interferon beta-1B to augment suppressor cell function. In press.